Abstract
CHICAGO-- Until now, researchers have assumed that if virus levels go up in patients on the new AIDS treatments that are helping HIV-infected people live longer, healthier lives, the treatment has failed. But new data presented here at the Fifth Conference on Retroviruses and Opportunistic Infections indicate that immune-cell levels can remain high even when the virus is thriving--perhaps because other factors besides viral levels can affect immune-cell production, powerful new tests suggest. But 12 groups also reported a down side to this good news: Long-term treatment with protease inhibitors causes a puzzling redistribution of body fat that could be an omen of other, more serious side effects.

This publication has 0 references indexed in Scilit: